Journal of Biotechnology & Biomaterials
Open Access

Abstract

For too long, poor case detection has continued to remain a major health care problem, resulting in a huge burden to both the patient (tremendous overtreatment/under treatment) & society, (huge implications of cost and drug resistance). Conventional testing methodologies for a variety of infectious and communicable diseases based on so called “Gold Standard” but grossly inadequate platforms have only added to the patient’s misfortune. Also the fact that to even take advantage of such existing tests a patient has to necessarily travel long distances to tertiary level centers to give his/her sample for testing and then undergo an agonizing wait for the results of the tests to be known and then for the treatment to get started. Currently MDx (Molecular Diagnostic) platforms using the real time PCR principles, considered most sensitive and specific, while promising greatly improved delivery of patient care through expedited diagnosis, improved treatment efficacy, have as a matter of fact neither delivered nor met the expectations of “quantum leap in laboratory testing standards”. Various complexities and short comings have led to the miniscule use of such a unique technology for the betterment of global healthcare settings.

Biography

Sumit Mitra has completed his Graduate degree in Organic Chemistry from St. Edmund’s College, Shillong and then completed his Master’s degree in Biochemistry from North East Hill University. His special subject was Biological Nitrogen Fixation under tutelage of Professor Amar Nath Rai, while also being extremely interested in basic Immunology. Soon after, he has joined the Indian In Vitro Diagnostic (IVD) industry and has served as an Application & Training Specialist in the fields of Clinical Chemistry, Immunoassays and Infectious Disease Diagnostics. With over two decades of experience in different roles in sales and marketing across diverse product portfolios, he is currently the Head of Global Business for Molbio Diagnostics, a JV between Tulip Group from Goa and Bigtec Laboratories in Bengaluru that seeks to change paradigms within the Molecular Diagnostic Landscape.

Email: mandirasumit@gmail.com